Sangamo Announces ASGCT 2024

Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures.

Our Pipeline and Programs

Clinical Trials

Indication Preclinical Phase 1/2 Pivotal Partner Anticipated Milestones*
Chronic Neuropathic Pain (Nav 1.7) Data presented at ASGCT 2023 Q4 24: Nav 1.7 IND submission
Prion Disease Data presented at Prion 2023 Q4 25: Prion CTA submission
Tauopathies As early as Q4 25: Tau IND submission
ALS/FTD alexion logo
Huntington's Disease takeda logo
Indication Preclinical Phase 1/2 Pivotal Partner Anticipated Milestones*
Hemophilia A (Giroctogene fitelparvovec) Data presented at ASH 2023 pfizer logo Mid-2024: Phase 3 AFFINE trial pivotal readout
Early 2025: BLA and MAA submissions
Fabry Disease (Isaralgagene civaparvovec) Data presented at WORLDSymposium 2024 IH24: Phase 1/2 STAAR study dosing completion
Renal Transplant (TX200) Six patients dosed in Phase 1/2 IH24: Phase 1/2 STEADFAST study dosing completion

Clinical Trials

Learn more about our approach to clinical trials.

Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.

View Clinical Trials


We seek collaborations that can extend or complement our leading genomic medicine capabilities

Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.

Our Partners

Sangamo and Alexion are collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.


Chroma Medicine has a research evaluation, option and license agreement with Sangamo to explore zinc finger proteins (ZFPs) for epigenetic editing in specified targets outside of the central nervous system.

Image: Pfizer Logo

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia A.


Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, has a research evaluation and option agreement with Sangamo to evaluate certain proprietary novel engineered cerebrospinal fluid-administered capsids with enhanced nervous system delivery, generated through Sangamo’s capsid engineering platform, SIFTER.

Image: Takeda Logo

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.


Sangamo has entered into an agreement with Voyager Therapeutics to license Voyager’s intravenous-administered delivery capsid, which has been shown in animal models to achieve the specific central nervous system coverage we believe to be required for Sangamo’s epigenetic regulation program for prion disease.

Interested in collaborating with us?

Contact Stephanie Seiler, Head of Business Development and Alliance Management

Contact Stephanie